Crinetics Pharmaceuticals Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Crinetics Pharmaceuticals de 51.3% y 53.3% por año respectivamente. Se prevé que el BPA crezca en un 49.1% al año. Se espera que la rentabilidad financiera sea de -32.8% en 3 años.
Información clave
51.3%
Tasa de crecimiento de los beneficios
49.13%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.4% |
| Tasa de crecimiento de los ingresos | 53.3% |
| Rentabilidad financiera futura | -32.78% |
| Cobertura de analistas | Good |
| Última actualización | 02 Jul 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
CRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution
The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements
Summary Crinetics Pharmaceuticals maintains a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for acromegaly. The company advances atumelnant, its oral ACTH receptor antagonist, with promising phase 2 data for CAH and ACTH-dependent Cushing's syndrome. Q1 2026 Palsonify revenues reached $10.3M, beating expectations, but the company's cash runway remains limited to at least 12 months. Ongoing late-stage trials and global regulatory submissions for Palsonify and atumelnant underpin the investment thesis, despite dilution and execution risks. Read the full article on Seeking AlphaCrinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data
Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...A Look At The Intrinsic Value Of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Key Insights The projected fair value for Crinetics Pharmaceuticals is US$37.65 based on 2 Stage Free Cash Flow to...Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking AlphaWe're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking AlphaMost Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Key Insights Crinetics Pharmaceuticals to hold its Annual General Meeting on 7th of June Salary of US$614.0k is part of...Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET. Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 418 | -285 | -220 | -339 | 8 |
| 12/31/2027 | 173 | -470 | -361 | -367 | 14 |
| 12/31/2026 | 69 | -512 | -418 | -391 | 14 |
| 3/31/2026 | 18 | -496 | -420 | -414 | N/A |
| 12/31/2025 | 8 | -465 | -384 | -378 | N/A |
| 9/30/2025 | 2 | -423 | -354 | -348 | N/A |
| 6/30/2025 | 1 | -370 | -306 | -300 | N/A |
| 3/31/2025 | 1 | -328 | -270 | -266 | N/A |
| 12/31/2024 | 1 | -298 | -234 | -230 | N/A |
| 9/30/2024 | 1 | -278 | -206 | -202 | N/A |
| 6/30/2024 | 1 | -259 | -187 | -180 | N/A |
| 3/31/2024 | 2 | -235 | -184 | -178 | N/A |
| 12/31/2023 | 4 | -215 | -173 | -169 | N/A |
| 9/30/2023 | 5 | -199 | -167 | -163 | N/A |
| 6/30/2023 | 5 | -184 | -161 | -160 | N/A |
| 3/31/2023 | 4 | -175 | -144 | -142 | N/A |
| 12/31/2022 | 5 | -164 | -117 | -115 | N/A |
| 9/30/2022 | 5 | -150 | -104 | -103 | N/A |
| 6/30/2022 | 5 | -136 | -91 | -90 | N/A |
| 3/31/2022 | 4 | -119 | -82 | -82 | N/A |
| 12/31/2021 | 1 | -108 | -89 | -89 | N/A |
| 9/30/2021 | N/A | -98 | -82 | -82 | N/A |
| 6/30/2021 | N/A | -89 | -74 | -74 | N/A |
| 3/31/2021 | N/A | -79 | -70 | -70 | N/A |
| 12/31/2020 | 0 | -74 | -62 | -62 | N/A |
| 9/30/2020 | 0 | -67 | -60 | -60 | N/A |
| 6/30/2020 | 1 | -63 | -55 | -55 | N/A |
| 3/31/2020 | 1 | -59 | -52 | -52 | N/A |
| 12/31/2019 | 1 | -50 | N/A | -46 | N/A |
| 9/30/2019 | 2 | -44 | N/A | -39 | N/A |
| 6/30/2019 | 2 | -38 | N/A | -31 | N/A |
| 3/31/2019 | 2 | -31 | N/A | -23 | N/A |
| 12/31/2018 | 2 | -27 | N/A | -19 | N/A |
| 9/30/2018 | 2 | -21 | N/A | -16 | N/A |
| 6/30/2018 | 2 | -16 | N/A | -13 | N/A |
| 3/31/2018 | 2 | -12 | N/A | -11 | N/A |
| 12/31/2017 | 2 | -9 | N/A | -9 | N/A |
| 12/31/2016 | 1 | -6 | N/A | -5 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que CRNX siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que CRNX siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que CRNX siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (53.3% al año) de CRNX crezcan más rápidamente que los del mercado US (12.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (53.3% al año) de CRNX crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: CRNX se prevé que no sea rentable en 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/05 05:48 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Crinetics Pharmaceuticals, Inc. está cubierta por 22 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |